vs

Side-by-side financial comparison of Cheer Holding, Inc. (CHR) and InfuSystem Holdings, Inc (INFU). Click either name above to swap in a different company.

Cheer Holding, Inc. is the larger business by last-quarter revenue ($71.0M vs $36.2M, roughly 2.0× InfuSystem Holdings, Inc). On growth, InfuSystem Holdings, Inc posted the faster year-over-year revenue change (7.0% vs -0.1%).

Cheer Holding, Inc. is a diversified holding company primarily operating in the Chinese market, with core business segments covering early childhood education services, mobile lifestyle platforms, digital content offerings, and integrated consumer solutions for households and enterprise partners across multiple demand scenarios.

InfuSystem Holdings, Inc. is a U.S.-headquartered healthcare provider specializing in infusion therapy solutions. It supplies programmable infusion pumps, matching disposable medical consumables, and professional clinical support services, serving oncology clinics, home healthcare providers, and acute care facilities across North America.

CHR vs INFU — Head-to-Head

Bigger by revenue
CHR
CHR
2.0× larger
CHR
$71.0M
$36.2M
INFU
Growing faster (revenue YoY)
INFU
INFU
+7.1% gap
INFU
7.0%
-0.1%
CHR

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
CHR
CHR
INFU
INFU
Revenue
$71.0M
$36.2M
Net Profit
$7.8M
Gross Margin
70.7%
56.4%
Operating Margin
11.7%
10.3%
Net Margin
10.9%
Revenue YoY
-0.1%
7.0%
Net Profit YoY
-37.5%
EPS (diluted)
$0.67
$0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CHR
CHR
INFU
INFU
Q4 25
$36.2M
Q3 25
$36.5M
Q2 25
$71.0M
$36.0M
Q1 25
$34.7M
Q4 24
$33.8M
Q3 24
$35.3M
Q2 24
$71.1M
$33.7M
Q1 24
$32.0M
Net Profit
CHR
CHR
INFU
INFU
Q4 25
Q3 25
$2.3M
Q2 25
$7.8M
$2.6M
Q1 25
$-267.0K
Q4 24
Q3 24
$1.8M
Q2 24
$12.4M
$717.0K
Q1 24
$-1.1M
Gross Margin
CHR
CHR
INFU
INFU
Q4 25
56.4%
Q3 25
57.1%
Q2 25
70.7%
55.2%
Q1 25
55.2%
Q4 24
53.8%
Q3 24
53.9%
Q2 24
73.4%
49.5%
Q1 24
51.5%
Operating Margin
CHR
CHR
INFU
INFU
Q4 25
10.3%
Q3 25
10.4%
Q2 25
11.7%
10.5%
Q1 25
1.8%
Q4 24
7.7%
Q3 24
9.2%
Q2 24
16.4%
5.5%
Q1 24
-2.6%
Net Margin
CHR
CHR
INFU
INFU
Q4 25
Q3 25
6.2%
Q2 25
10.9%
7.2%
Q1 25
-0.8%
Q4 24
Q3 24
5.1%
Q2 24
17.5%
2.1%
Q1 24
-3.5%
EPS (diluted)
CHR
CHR
INFU
INFU
Q4 25
$0.09
Q3 25
$0.11
Q2 25
$0.67
$0.12
Q1 25
$-0.01
Q4 24
$0.05
Q3 24
$0.08
Q2 24
$1.23
$0.03
Q1 24
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CHR
CHR
INFU
INFU
Cash + ST InvestmentsLiquidity on hand
$3.2M
Total DebtLower is stronger
$19.6M
Stockholders' EquityBook value
$322.1M
$57.3M
Total Assets
$362.7M
$100.6M
Debt / EquityLower = less leverage
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CHR
CHR
INFU
INFU
Q4 25
$3.2M
Q3 25
$955.0K
Q2 25
$720.0K
Q1 25
$1.5M
Q4 24
$527.0K
Q3 24
$380.0K
Q2 24
$186.1M
$146.0K
Q1 24
$822.0K
Total Debt
CHR
CHR
INFU
INFU
Q4 25
$19.6M
Q3 25
$20.9M
Q2 25
$26.3M
Q1 25
$28.7M
Q4 24
$23.9M
Q3 24
$28.0M
Q2 24
$34.2M
Q1 24
$29.9M
Stockholders' Equity
CHR
CHR
INFU
INFU
Q4 25
$57.3M
Q3 25
$55.5M
Q2 25
$322.1M
$54.5M
Q1 25
$55.1M
Q4 24
$57.5M
Q3 24
$55.5M
Q2 24
$286.1M
$53.5M
Q1 24
$52.3M
Total Assets
CHR
CHR
INFU
INFU
Q4 25
$100.6M
Q3 25
$98.9M
Q2 25
$362.7M
$100.8M
Q1 25
$104.3M
Q4 24
$103.6M
Q3 24
$105.3M
Q2 24
$333.2M
$108.5M
Q1 24
$104.8M
Debt / Equity
CHR
CHR
INFU
INFU
Q4 25
0.34×
Q3 25
0.38×
Q2 25
0.48×
Q1 25
0.52×
Q4 24
0.41×
Q3 24
0.50×
Q2 24
0.64×
Q1 24
0.57×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CHR
CHR
INFU
INFU
Operating Cash FlowLast quarter
$3.9M
$7.1M
Free Cash FlowOCF − Capex
$7.0M
FCF MarginFCF / Revenue
19.3%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
0.51×
TTM Free Cash FlowTrailing 4 quarters
$23.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CHR
CHR
INFU
INFU
Q4 25
$7.1M
Q3 25
$8.5M
Q2 25
$3.9M
$7.0M
Q1 25
$1.8M
Q4 24
$7.9M
Q3 24
$9.8M
Q2 24
$-6.7M
$2.3M
Q1 24
$377.0K
Free Cash Flow
CHR
CHR
INFU
INFU
Q4 25
$7.0M
Q3 25
$8.4M
Q2 25
$6.8M
Q1 25
$1.6M
Q4 24
$7.4M
Q3 24
$9.8M
Q2 24
$2.0M
Q1 24
$195.0K
FCF Margin
CHR
CHR
INFU
INFU
Q4 25
19.3%
Q3 25
23.1%
Q2 25
18.9%
Q1 25
4.7%
Q4 24
21.9%
Q3 24
27.7%
Q2 24
5.9%
Q1 24
0.6%
Capex Intensity
CHR
CHR
INFU
INFU
Q4 25
0.4%
Q3 25
0.2%
Q2 25
0.6%
Q1 25
0.4%
Q4 24
1.6%
Q3 24
0.1%
Q2 24
1.0%
Q1 24
0.6%
Cash Conversion
CHR
CHR
INFU
INFU
Q4 25
Q3 25
3.76×
Q2 25
0.51×
2.70×
Q1 25
Q4 24
Q3 24
5.45×
Q2 24
-0.54×
3.22×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CHR
CHR

Segment breakdown not available.

INFU
INFU

Patient Services$20.0M55%
Device Solutions$14.4M40%
Other$1.9M5%

Related Comparisons